Plant Name: Dalbergia odorifera
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| RECQL; TDP1; BLM; MIF; GLO1; HPGD; ALOX12; HSD17B1; AKR1B1; HSD17B10; ALOX15; NOX4; ALDH1A1; TNKS; PARP1; TNKS2; AOX1; APEX1; CD38; POLB; | |
| MGAM; ACHE; | |
| CDK2; FLT3; ABL1; EGFR; MAPK1; CDK6; GSK3B; | |
| CA2; CA12; CA7; CA4; | |
| ESR2; ESR1; | |
| ESRRB; ESRRA; | |
| ALOX5; MAOA; ALDH2; XDH; | |
| KDM4E; | |
| MMP12; MMP9; MMP2; | |
| HIF1A; TP53; NFKB1; | |
| ABCG2; | |
| SLCO1B3; SLCO1B1; | |
| HTT; RAB9A; NPC1; LMNA; TTR; MCL1; MAPT; THPO; APP; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | CDK2 | Cyclin-dependent kinase 2 | P24941 | CHEMBL301 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.589E-14 | 1.435E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.737E-12 | 4.787E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.332E-11 | 2.874E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.552E-10 | 8.891E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.082E-10 | 1.114E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.984E-09 | 6.352E-07 | ABL1, CA2, CA7, CD38, CDK6, EGFR, HIF1A, HTT, MAPK1, MIF, NPC1, PARP1, TNKS, TNKS2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.121E-08 | 2.906E-06 | ABL1, CA2, CA7, EGFR, HIF1A, HTT, MAPK1, NPC1, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.214E-08 | 3.109E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.153E-08 | 7.304E-06 | CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.786E-08 | 8.677E-06 | BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, GLO1, MMP12, MMP2, MMP9, PARP1, TNKS, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.586E-08 | 1.781E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 8.586E-08 | 1.781E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.533E-07 | 2.981E-05 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.981E-07 | 3.719E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.348E-07 | 4.333E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.122E-07 | 5.572E-05 | ALOX12, ALOX15, ALOX5, HPGD |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 4.173E-07 | 7.044E-05 | ABL1, GSK3B, MAPT, MCL1, PARP1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 6.061E-07 | 9.848E-05 | AKR1B1, ALDH1A1, ALDH2, AOX1, XDH |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 2.389E-06 | 3.293E-04 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
| MF | GO:0005488; binding | GO:0051287; NAD binding | 2.675E-06 | 3.618E-04 | ALDH1A1, ALDH2, AOX1, HPGD, PARP1 |
| BP | GO:0009987; cellular process | GO:1903376; regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 2.744E-06 | 3.666E-04 | HIF1A, MCL1, PARP1 |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 4.105E-06 | 5.258E-04 | APP, EGFR, MAPT |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 4.105E-06 | 5.258E-04 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 5.174E-06 | 6.510E-04 | CYP1A2, EGFR, MAPK1, MMP9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 5.957E-06 | 7.287E-04 | CA2, CA4, EGFR, HPGD, SLCO1B1, SLCO1B3, TSHR |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 6.265E-06 | 7.545E-04 | BLM, GSK3B, HIF1A, HTT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 6.849E-06 | 8.105E-04 | CD38, CYP1A2, EGFR, ESR1, ESRRA, HPGD |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 8.020E-06 | 9.339E-04 | GSK3B, HTT, MAPT |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 8.677E-06 | 9.893E-04 | ABL1, ALOX15, APP, EGFR, MIF, NOX4, THPO |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.550E-06 | 1.072E-03 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0008134; transcription factor binding | 1.097E-05 | 1.195E-03 | APEX1, ESR1, ESRRB, FLT3, GSK3B, HIF1A, HTT, MAPK1, NFKB1, PARP1, TP53 |
| BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 1.370E-05 | 1.388E-03 | AOX1, XDH |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.370E-05 | 1.388E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.370E-05 | 1.388E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.370E-05 | 1.388E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.370E-05 | 1.388E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.452E-05 | 1.444E-03 | ABL1, CYP1B1, GSK3B, HPGD, HTT, MAPT, MCL1, MMP9, NOX4, TP53, XDH |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.626E-05 | 1.567E-03 | ACHE, ALDH1A1, EGFR, HSD17B1, TTR |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.695E-05 | 1.619E-03 | ABL1, APEX1, CYP1A1, CYP1B1, CYP2D6, ESR2, GSK3B, HSD17B10, MAOA, MAPK1, MCL1, MMP2, NFKB1, NOX4, PARP1, TP53 |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 1.895E-05 | 1.779E-03 | ABL1, APEX1, APP, BLM, CD38, CDK2, CYP2D6, ESR1, ESR2, ESRRA, GSK3B, HIF1A, MAPT, MCL1, MIF, MMP12, MMP9, NFKB1, NPC1, PARP1, TNKS, TNKS2, TP53, XDH |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.152E-05 | 1.977E-03 | CA12, CA2, CA4, CA7 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 2.580E-05 | 2.331E-03 | ABL1, ACHE, AKR1B1, APEX1, APP, CA4, EGFR, HTT, NOX4, NPC1, TNKS2 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 2.714E-05 | 2.433E-03 | ABL1, ACHE, CD38, EGFR, HIF1A, MIF, MMP12 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 3.252E-05 | 2.856E-03 | MAPK1, TNKS, TNKS2 |
| CC | GO:0044422; organelle part | GO:0000781; chromosome, telomeric region | 3.478E-05 | 3.005E-03 | APEX1, BLM, CDK2, PARP1, TNKS, TNKS2 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 3.766E-05 | 3.216E-03 | ABL1, ALOX12, APP, EGFR, HIF1A, MAPK1, MMP9, NOX4, TP53 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.101E-05 | 3.357E-03 | CYP2D6, CYP3A4 |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 4.101E-05 | 3.357E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.101E-05 | 3.357E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.101E-05 | 3.357E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.101E-05 | 3.357E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.101E-05 | 3.357E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 4.874E-05 | 3.902E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 5.037E-05 | 4.003E-03 | CD38, CYP1A1, HIF1A, LMNA, MMP2, NOX4, TP53 |
| BP | GO:0008152; metabolic process | GO:0045893; positive regulation of transcription, DNA-templated | 5.142E-05 | 4.057E-03 | APP, BLM, CD38, CDK2, EGFR, ESR1, ESR2, ESRRA, ESRRB, HIF1A, MAPK1, MMP12, NFKB1, PARP1, TNKS, TP53 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 5.409E-05 | 4.222E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0009987; cellular process | GO:2001020; regulation of response to DNA damage stimulus | 5.481E-05 | 4.263E-03 | ABL1, EGFR, MAPT, MCL1, MIF, PARP1 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 6.294E-05 | 4.792E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0034097; response to cytokine | 6.893E-05 | 5.158E-03 | ALOX15, CD38, FLT3, GSK3B, HIF1A, MAPK1, MCL1, NFKB1, TP53 |
| BP | GO:0009987; cellular process | GO:0045787; positive regulation of cell cycle | 7.040E-05 | 5.214E-03 | ABL1, APEX1, APP, CDK2, CYP1A1, EGFR, MIF, TP53 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 7.268E-05 | 5.258E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 7.886E-05 | 5.557E-03 | ABL1, AKR1B1, APEX1, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 8.181E-05 | 5.656E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.181E-05 | 5.656E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 8.181E-05 | 5.656E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.336E-05 | 5.744E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0034641; cellular nitrogen compound metabolic process | 1.071E-04 | 7.129E-03 | ABCG2, ABL1, ACHE, AOX1, APEX1, APP, BLM, CD38, CDK2, CYP1B1, CYP2C9, CYP2D6, CYP3A4, EGFR, ESR1, ESR2, ESRRA, ESRRB, GLO1, HIF1A, HSD17B10, KDM4E, MAOA, MAPK1, NFKB1, PARP1, POLB, RECQL, SMN1, SMN2, TDP1, TP53, TTR, XDH |
| MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 1.139E-04 | 7.470E-03 | APEX1, BLM, POLB, TP53 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.139E-04 | 7.470E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 1.207E-04 | 7.844E-03 | ABL1, MCL1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.214E-04 | 7.844E-03 | CYP19A1, CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 1.214E-04 | 7.844E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.360E-04 | 8.426E-03 | ALOX12, ALOX15 |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.362E-04 | 8.426E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.362E-04 | 8.426E-03 | APP, GSK3B, PARP1 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.360E-04 | 8.426E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 1.360E-04 | 8.426E-03 | BLM, RECQL |
| BP | GO:0032501; multicellular organismal process | GO:0051240; positive regulation of multicellular organismal process | 1.377E-04 | 8.497E-03 | ABL1, ALOX12, APP, CA2, CD38, CYP1B1, EGFR, ESRRB, HIF1A, MAPT, MIF, MMP12, MMP9, NFKB1, PARP1, THPO |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.405E-04 | 8.644E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, NOX4, RAB9A, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.521E-04 | 9.203E-03 | CYP19A1, CYP3A4, ESR1 |
| BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 1.600E-04 | 9.652E-03 | ACHE, ALDH1A1, ALDH2, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, GSK3B, HSD17B10, MAOA, MGAM, TP53, XDH |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 1.661E-04 | 9.965E-03 | CA2, CD38, EGFR, FLT3, NPC1, PARP1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.934E-16 | 3.455E-12 | ALOX12, ALOX15, ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, TBXAS1, XDH |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.478E-10 | 4.435E-08 | CYP2C9; APP; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.132E-09 | 3.659E-07 | ALDH2; MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 8.397E-09 | 3.758E-07 | MGAM; MAOA; ALOX15; AKR1B1; ALOX12; CYP2C19; CYP3A4; CYP19A1; HSD17B10; CYP2C9; ALDH2; HSD17B1; ALOX5; TBXAS1; CYP1A2; ALDH1A1; CYP1A1; CD38; AOX1; XDH |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.666E-08 | 5.963E-07 | GSK3B; CDK6; FLT3; MMP2; CDK2; ABL1; MAPK1; HIF1A; TP53; MMP9; EGFR; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.250E-09 | 3.659E-07 | CYP2C9; MAOA; CYP2D6; CYP1A2; AOX1; CYP3A4; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 9.227E-08 | 2.065E-06 | CYP2C9; ALOX5; ALOX15; TBXAS1; ALOX12; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.145E-08 | 1.571E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.229E-07 | 2.445E-06 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; AOX1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.830E-08 | 1.571E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.477E-07 | 4.434E-06 | CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.081E-07 | 1.033E-05 | GSK3B; CDK2; MAPK1; TP53; EGFR; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.167E-06 | 1.306E-05 | CDK6; ABL1; CYP1B1; MAPK1; TP53; MMP9; EGFR; NFKB1; MCL1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.557E-07 | 5.307E-06 | MMP2; MAPK1; MMP9; TP53; EGFR |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.515E-06 | 1.595E-05 | MMP2; MAPK1; ESR1; MMP9; EGFR; ESR2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.967E-07 | 6.839E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 9.808E-07 | 1.170E-05 | HSD17B1; ALOX5; CYP1A1; CYP1B1; CYP19A1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.956E-06 | 3.934E-05 | CDK6; MAPK1; TP53; EGFR; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.435E-06 | 6.565E-05 | MMP2; MAPK1; TP53; HIF1A; ESR1; MMP9; EGFR |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.264E-06 | 4.017E-05 | FLT3; MAPK1; TP53; HIF1A; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 6.091E-06 | 5.192E-05 | GSK3B; MAPK1; ESR1; NFKB1; ESR2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.129E-05 | 8.086E-05 | PARP1; LMNA; MAPK1; TP53; NFKB1; MCL1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 6.521E-06 | 5.306E-05 | CDK6; ABL1; MAPK1; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 9.568E-06 | 7.136E-05 | GSK3B; CDK6; CDK2; RAB9A; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.435E-05 | 9.878E-05 | CDK6; CDK2; MAPK1; TP53; MMP9; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.048E-05 | 2.020E-04 | GSK3B; CDK6; CDK2; MAPK1; TP53; EGFR; NFKB1; MCL1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.684E-06 | 5.087E-05 | SLCO1B1; CA2; SLCO1B3; CYP3A4; ABCG2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 9.593E-05 | 5.050E-04 | POLB; CDK6; CDK2; MAPK1; TP53; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 6.701E-05 | 3.998E-04 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 7.258E-05 | 4.191E-04 | GSK3B; ABL1; MAPK1; TP53; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.922E-05 | 3.038E-04 | CDK6; MAPK1; TP53; EGFR |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 8.480E-05 | 4.744E-04 | GSK3B; CDK6; CDK2; ABL1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.181E-04 | 6.038E-04 | GSK3B; MAPK1; TP53; EGFR; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.668E-05 | 2.345E-04 | GSK3B; MAPK1; TP53; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 8.854E-05 | 4.803E-04 | CDK6; MAPK1; TP53; EGFR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.250E-04 | 6.140E-04 | CDK6; MAPK1; TP53; EGFR |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.546E-07 | 5.307E-06 | CA12; CA2; CA4; CA7 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.500E-04 | 1.492E-03 | APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 8.086E-04 | 3.147E-03 | GSK3B; CDK2; CD38; TP53; NFKB1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.743E-04 | 1.197E-03 | GSK3B; ABL1; MAPK1; EGFR |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 4.800E-04 | 1.998E-03 | HPGD; FLT3; TP53; MMP9; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.624E-04 | 1.197E-03 | CDK6; CDK2; TP53; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.217E-04 | 2.122E-03 | MAPK1; HIF1A; EGFR; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.262E-03 | 7.787E-03 | MAPK1; MAPT; TP53; EGFR; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.323E-03 | 7.845E-03 | GSK3B; MAPK1; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.793E-03 | 1.646E-02 | MMP2; MAPK1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 4.333E-03 | 1.337E-02 | MMP2; MAPK1; EGFR |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 9.107E-03 | 2.367E-02 | ABL1; MAPK1; EGFR; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 5.793E-03 | 1.646E-02 | MAPK1; HIF1A; EGFR |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.453E-03 | 5.418E-03 | GSK3B; MAPK1; TP53 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 3.944E-03 | 1.261E-02 | THPO; FLT3; CD38 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.139E-03 | 4.337E-03 | FLT3; MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.332E-03 | 2.018E-02 | MAPK1; MMP9; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 6.282E-03 | 1.757E-02 | GSK3B; MAPK1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 8.885E-03 | 2.367E-02 | ALOX5; MAPK1; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.403E-02 | 3.305E-02 | POLB; GSK3B; TP53; NFKB1 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.977E-03 | 6.939E-03 | CDK6; CDK2; TP53 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.665E-03 | 6.009E-03 | ABL1; MAPK1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.301E-03 | 2.378E-02 | MAPK1; TP53; NFKB1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.228E-02 | 3.011E-02 | CDK2; MAPK1; EGFR |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.085E-02 | 2.734E-02 | GSK3B; ABL1; MAPK1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.463E-02 | 3.401E-02 | GSK3B; ESRRB; MAPK1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.939E-02 | 4.233E-02 | THPO; AOX1; MCL1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.939E-02 | 4.233E-02 | CD38; MAPK1; EGFR |
| hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 6.888E-04 | 2.740E-03 | ALDH2; AOX1; HSD17B10 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.364E-02 | 4.977E-02 | MAPK1; HIF1A |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.977E-02 | 4.265E-02 | MAPK1; HIF1A |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 2.695E-04 | 1.197E-03 | MAOA; AOX1; MIF |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.916E-02 | 4.233E-02 | ALDH2; AKR1B1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.795E-02 | 4.068E-02 | MAPK1; NFKB1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 2.259E-04 | 1.064E-03 | POLB; PARP1; APEX1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.678E-02 | 3.851E-02 | GSK3B; TP53 |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 1.400E-02 | 3.305E-02 | ALDH2; MAOA |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.348E-02 | 3.260E-02 | MAOA; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.194E-02 | 2.969E-02 | CYP3A4; XDH |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.873E-03 | 1.454E-02 | MAPK1; TP53 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 4.232E-03 | 1.329E-02 | MAPK1; EGFR |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.209E-03 | 1.528E-02 | MGAM; AKR1B1 |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 9.126E-03 | 2.367E-02 | ALDH2; GLO1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 7.439E-03 | 2.018E-02 | ALDH2; AKR1B1 |
| hsa00760 | Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | 4.873E-03 | 1.454E-02 | AOX1; CD38 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.079E-03 | 1.021E-02 | CA2; CA4 |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 3.351E-03 | 1.091E-02 | ALDH2; MAOA |
| hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 1.678E-03 | 6.009E-03 | MAOA; MIF |
| hsa00750 | Vitamin B6 metabolism_Homo sapiens_hsa00750 | 2.141E-02 | 4.562E-02 | AOX1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.269E-04 | 6.140E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CDK2; HIF1A; TP53; FLT3; ABL1; MMP9; EGFR; MAPK1; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | CDK2; FLT3; ABL1 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR; MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; AKR1B1; ESRRA |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ABL1; ESR1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1 |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR; APP |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR; PARP1; MMP2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; ABL1; EGFR; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; NFKB1; MGAM |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; PARP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ALDH2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; PARP1; ALDH2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; ESRRA |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; TBXAS1; MMP12; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | CDK2; EGFR; EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; MGAM; GSK3B |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; EGFR; MMP2 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; EGFR |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; MAOA; GSK3B; MAPT; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; ABL1 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Thymoma | C37, D15.0 | CDK2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; TBXAS1 |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; FLT3; FLT3; EGFR; EGFR; EGFR; ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CDK2; HIF1A; TP53; FLT3; FLT3; ABL1; MMP9; NFKB1; ACHE; EGFR; ESR1; ESR1; MAPK1; PARP1; MMP2; MCL1; GSK3B; CD38; APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | MGAM |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; MMP2; ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MIF; MMP12 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| NA: NA | Menopausal disorder | NA | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9; EGFR; EGFR |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; CD38 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |